iBio (IBIO) Stock Is Heading Up Ahead Of A Conference Call

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is headed up in the market this morning, but with no press releases or SEC filings, many are wondering why. Here’s how I see it:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Gains On Coming Conference Call

iBio is focused on the development of plant-based vaccines. In particular, the company took center stage when it began development of multiple vaccine candidates in the fight against the COVID-19 pandemic.

Beyond its development of vaccines, a major source of value at IBIO is its FastPharming Facility. Developed using funds provided by the United States government, the FastPharming Facility has the capability of manufacturing plant-based vaccines and therapies at a lightning-like pace.

This is where we get to the story that I believe is moving the needle for IBIO stock today.

Medicago, another company working to develop plant-based vaccines, will be holding an investor conference call today from 4pm to 5pm GMT. The call is being offered to provide an updae surrounding the safety & immunology of a plant-derived coronavirus-like particle vaccine candidate in adults ages 18 to 55. The presenters will also discuss an interim report after the second dose of the vaccine candidate in patients.

So, Medicago is a competitor, what does this have to do with IBIO?

Should Medicago develop a plant-derived coronavirus vaccine that proves to be safe, well-tolerated, and effective, the next step is going to be fast-paced manufacturing. After all, a vaccine does nothing if there’s not enough of it to commercialize.

That’s where IBIO comes in. With the company’s FastPharming Facility, it has the ability to manufacture plant-derived vaccines and therapeutics faster than any other manufacturer in the country. That will be overwhelmingly attractive when Medicago starts looking for manufacturing partners.

The Bottom Line

The bottom line here is that the value in IBIO goes far beyond its own work in developing a COVID-19 vaccine. The company’s FastPharming Facility represents a tremendous opportunity given the current COVID-19 pandemic and the potential for future pandemics to take hold. All in all, IBIO stock is hard to ignore.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts and gain access to Joshua’s investing portfolio!

Subscribe Now

All we need is your email address.

Click here to subscribe if reading on mobile. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.